Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.75 Consensus PT from Analysts
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price […]